Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Loncastuximab Tesirine in Previously Treated Waldenström Macroglobulinemia
NCT05190705Phase 2Active, not recruiting
- Start
- Feb 2022
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of loncastuximab tesirine in Waldenström macroglobulinemia (WM). Primary endpoint: Overall Response Rate at 6 months. Started Feb 2022; status: active, not recruiting.
02
Drugs
loncastuximab tesirine
03
Conditions
Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT05190705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05190705.